Our response to UK health regulator’s rejection of lecanemab as treatment for Alzheimer’s disease
Today, the UK’s medicines regulator, the MHRA, approved the new Alzheimer’s drug, lecanemab, for use in the UK. However, an interim provisional decision by the National Institute for Health and Care Excellence (NICE) has deemed lecanemab not cost-effective for the NHS. As a result, for now at least, the drug will only be available privately.
Date posted: